Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L F Van Gaal

Showing results (1-10 of 77) with videos related to

Pageof 8
Sort By:
Journal of Endocrinological Investigation|June 6, 2006
New approaches for the management of patients with multiple cardiometabolic risk factorsL F Van Gaal, F Peiffer
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|July 18, 2002
Obesity, haemostasis and the fibrinolytic systemI Mertens, L F Van Gaal
Drugs|August 10, 2000
Promising new approaches to the management of obesityI L Mertens, L F Van Gaal
Revue Medicale De Liege|July 23, 2005
[Type 2 diabetes, in the heart of the metabolic syndrome: plea for a global approach]A J Scheen, L F Van Gaal
Revue Medicale De Liege|April 1, 2008
[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes]A J Scheen, L F Van Gaal
Revue Medicale De Liege|November 5, 2013
[Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes]A J Scheen, L F Van Gaal
Journal of Endocrinological Investigation|June 30, 2017
Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic optionsA A Verhaegen, L F Van Gaal
Revue Medicale De Liege|September 23, 2010
[Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes]A J Scheen, L F Van Gaal
Revue Medicale De Liege|April 10, 2012
[Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination]A J Scheen, L F Van Gaal
Revue Medicale De Liege|April 24, 2010
[Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes]A J Scheen, L F Van Gaal
Pageof 8

Showing results (1-10 of 77) with videos related to

Sort By:
Pageof 8
Journal of Endocrinological Investigation|June 6, 2006
New approaches for the management of patients with multiple cardiometabolic risk factorsL F Van Gaal, F Peiffer
Obesity Reviews : an Official Journal of the International Association for the Study of Obesity|July 18, 2002
Obesity, haemostasis and the fibrinolytic systemI Mertens, L F Van Gaal
Drugs|August 10, 2000
Promising new approaches to the management of obesityI L Mertens, L F Van Gaal
Revue Medicale De Liege|July 23, 2005
[Type 2 diabetes, in the heart of the metabolic syndrome: plea for a global approach]A J Scheen, L F Van Gaal
Revue Medicale De Liege|April 1, 2008
[Sitagliptine (Januvia): incretin enhancer potentiating insulin secretion for the treatment of type 2 diabetes]A J Scheen, L F Van Gaal
Revue Medicale De Liege|November 5, 2013
[Jentadueto, fixed combination of linagliptin plus metformin for the treatment of type 2 diabetes]A J Scheen, L F Van Gaal
Journal of Endocrinological Investigation|June 30, 2017
Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic optionsA A Verhaegen, L F Van Gaal
Revue Medicale De Liege|September 23, 2010
[Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes]A J Scheen, L F Van Gaal
Revue Medicale De Liege|April 10, 2012
[Linagliptin (Trajenta): a selective DPP-4 inhibitor with limited renal elimination]A J Scheen, L F Van Gaal
Revue Medicale De Liege|April 24, 2010
[Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes]A J Scheen, L F Van Gaal
Pageof 8